Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2020

Filed with the SEC on Sep 11, 2020 and accepted by EDGAR at Sep 11, 2020, 16:27 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-05-01 to 2020-07-31$0us-gaap:Revenues
Research and development3 months2020-05-01 to 2020-07-31$270.6kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-05-01 to 2020-07-31−$881.7kus-gaap:OperatingIncomeLoss
Interest expense3 months2020-05-01 to 2020-07-31$388us-gaap:InterestExpense
Net income3 months2020-05-01 to 2020-07-31−$883.9kus-gaap:NetIncomeLoss
Diluted EPS3 months2020-05-01 to 2020-07-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2020-05-01 to 2020-07-311,678,572,167 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2020-05-01 to 2020-07-31−$551.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-07-31$2.2mus-gaap:Cash
Current assetsAt period end2020-07-31$2.3mus-gaap:AssetsCurrent
Total assetsAt period end2020-07-31$7.4mus-gaap:Assets
Current liabilitiesAt period end2020-07-31$1.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-07-31$1.2mus-gaap:Liabilities
Shareholders' equityAt period end2020-07-31$6.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-20-003111. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.